


CLAIMS

1. A process for preparation of a low toxicity, stable oxazaphosphorine-containing composition comprising an oxazaphosphorine antineoplastic,
5 mesna and an etherified β -cyclodextrin; the process comprising the steps of:

- i) adding the oxazaphosphorine antineoplastic to an aqueous solution of an etherified β -cyclodextrin;
- 10 ii) adding mesna as such or as an aqueous solution optionally containing an etherified β -cyclodextrin to the oxazaphosphorine solution of step (i); and
- iii) mixing the resultant aqueous solution and, optionally, making up the volume with water.

15 2. A process as claimed in Claim 1, wherein the oxazaphosphorine antineoplastic is of the formula:



20 in which at least two of R₁, R₂ and R₃ independently are 2-chloroethyl and the remaining R radical is hydrogen.

3. A process as claimed in Claim 2, wherein the oxazaphosphorine antineoplastic is Cyclophosphamide (R₁ = R₂ = chloroethyl & R₃ =
25 hydrogen).

4. A process as claimed in Claim 2, wherein the oxazaphosphorine antineoplastic is Ifosfamide (R₁ = R₃ = chloroethyl & R₂ = hydrogen).

5. A process as claimed in any one of the preceding claims, wherein the etherified β -cyclodextrin used is Hydroxypropyl Beta Cyclodextrin (HPBCD).
- 5 6. A process as claimed in Claim 5, wherein the molar substitution of HPBCD is from about 0.5 to about 1.2.
7. A process as claimed in any one of the preceding claims, wherein the oxazaphosphorine antineoplastic content of the composition is from about
10 1 mg/ml to about 1000 mg/ml.
8. A process as claimed in Claim 7, wherein said oxazaphosphorine antineoplastic content is from about 25 mg/ml to about 750 mg/ml.
- 15 9. A process as claimed in Claim 8, wherein said oxazaphosphorine antineoplastic content is from about 50 mg/ml to about 500 mg/ml.
10. A process as claimed in Claim 9, wherein said oxazaphosphorine antineoplastic content is about 50 mg/ml.
- 20 11. A process as claimed in Claim 9, wherein said oxazaphosphorine antineoplastic content is about 500 mg/ml.
12. A process as claimed in any one of the preceding claims, wherein the ratio
25 of oxazaphosphorine antineoplastic to mesna is in the range of about 20 : 1 to about 1 : 2 on a weight basis.
13. A process as claimed in claim 12, wherein the ratio of oxazaphosphorine antineoplastic to mesna is in the range of about 10 : 1 to about 1 : 1 on a
30 weight basis.

14. A process as claimed in claim 13, wherein the ratio of oxazaphosphorine antineoplastic to mesna is 10 : 2 on a weight basis.
- 5 15. A process as claimed in claim 13, wherein the ratio of oxazaphosphorine antineoplastic to mesna is 10 : 6 on a weight basis.
16. A process as claimed in any one of the preceding claims, wherein the content of etherified β -cyclodextrin in the composition is about 1% to about 60% w/v.
- 10 17. A process as claimed in Claim 16, wherein said etherified β -cyclodextrin content is about 2.5% to about 40% w/v.
18. A process as claimed in Claim 17, wherein said etherified β -cyclodextrin content is about 5% to about 20% w/v.
- 15 19. A process as claimed in any one of the preceding claims, wherein one or more conventional parenteral additives are incorporated into the aqueous solution of Claim 1 step (i) or Claim 1 step (ii) or in water used for making up the volume in Claim 1 step (iii).
- 20 20. A process as claimed in any one of the preceding claims, wherein said mixture of resultant aqueous solutions is sterilized by filtering through a sterilising grade filter.
- 25 21. A process as claimed in Claim 20, wherein the filtrate from the sterilising grade filter is aseptically filled into sterile containers and the filled containers are sealed.
- 30 22. A process as claimed in Claim 1 and substantially as herein before described with reference to any of the Examples.

23. A stable oxazaphosphorine-containing composition obtainable by a process as claimed in any one of the preceding claims.
24. A stable oxazaphosphorine-containing composition prepared by a process as claimed in any one of the preceding claims.
25. The use of a stable oxazaphosphorine-containing composition as defined in Claim 23 or Claim 24 in the manufacture of a medicament for the treatment of malignant disease.
26. A method of treating a malignant disease comprising administering to a patient suffering said disease an effective amount of a sterile stable oxazaphosphorine-containing composition as defined in Claim 23 or Claim 24.